George Bakris
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1821021619
Payments from drug & device makers
Across 362 payments — averaging $1184.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$138K
- Sanofi-aventis U.S. LLC$39K
- Novo Nordisk$35K
- Merck$24K
- AbbVie$23K
- AstraZeneca$21K
- plus $149K from 27 others
Across 15 payments — averaging $2862.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$34K
- Janssen Scientific Affairs, LLC$7K
- Bayer$2K
What the payments were for
- Consulting fees$282,95670%
- Speaking & faculty fees$49,35712%
- Travel & lodging$62,32915%
- Food & beverage$8,1302%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 126 | $138,351 |
| Sanofi-aventis U.S. LLC | 11 | $38,915 |
| Novo Nordisk | 40 | $35,371 |
| Merck | 28 | $24,148 |
| AbbVie | 1 | $22,583 |
| AstraZeneca | 32 | $20,709 |
| Johnson & Johnson | 13 | $18,869 |
| Janssen Scientific Affairs, LLC | 11 | $17,390 |
| Astrazeneca UK Limited | 9 | $15,123 |
| Novo Nordisk AS | 9 | $14,315 |
| Janssen Research & Development, LLC | 10 | $12,689 |
| Alnylam Pharmaceuticals Inc. | 9 | $12,540 |
| Vifor Pharma, Inc. | 18 | $11,986 |
| Boehringer Ingelheim MENA (scientific Office) Fz-llc | 2 | $6,394 |
| Gilead | 2 | $5,110 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | 3 | $4,909 |
| Janssen Global Services, LLC | 2 | $4,738 |
| Ardelyx, Inc. | 1 | $4,600 |
| Boehringer Ingelheim International GmbH | 4 | $3,310 |
| UCB SA | 3 | $3,203 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $2,720 |
| Esperion Therapeutics, Inc. | 10 | $2,578 |
| Amgen | 1 | $2,075 |
| CSL Behring | 1 | $2,043 |
| Medtronic(2 entities) | 3 | $1,785 |
| F. Hoffmann-la Roche AG | 1 | $1,120 |
| Genentech, Inc. | 1 | $745 |
| Calliditas Therapeutics US Inc. | 1 | $104 |
| Astrazeneca AB | 3 | $91 |
| Lexicon Pharmaceuticals, Inc. | 1 | $88 |
| Boehringer Ingelheim | 2 | $77 |
| Fresenius USA Marketing, Inc. | 1 | $52 |
| Travere Therapeutics, Inc. | 2 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$81,909
- Non-Covered$58,395
- AVAPRO$28,507
- Victoza$26,930
- INVOKANA$26,134
- Veltassa$15,963
- FARXIGA$10,625
- NO PRODUCT DISCUSSED$10,312
- MICARDIS$6,394
- LOKELMA$5,480
- JARDIANCE$3,310
- NEXLETOL$2,392
- NEXLIZET$2,392
- KRYSTEXXA$2,075
- Non-Covered Product$1,865
- Levemir$228
- NovoLog$228
- NovoLog Mix 70/30$228
- XARELTO$124
- TARPEYO$104
How this compares
$428,774 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 11 | $896 |
| Amlodipine Besylate | 32 | $223 |
| Olmesartan Medoxomil | 18 | $197 |
| Carvedilol | 17 | $157 |
| Spironolactone | 13 | $116 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Chicago
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Wenyu HuangChicago$639K
- Silvana PannainChicago$575K
- Tamara VokesChicago$448K
- William LoweChicago$372K
- Rajesh JainChicago$285K
- Louis PhilipsonChicago$236K
- Elena BarengoltsChicago$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.